Literature DB >> 866885

A review of the findings on computed cranial tomography following intravenous contrast media.

K R Davis, P F New, O J Solis, G H Roberson.   

Abstract

The diagnostic contribution of contrast enhancement by intravenous injection of meglumine diatrizoate was assessed in 121 patients who received both plain and contrast enhanced cranial CT scans. The use of contrast enhancement was found to provide both an increased sensitivity in detection of lesions and some improvement in pathological differentiation of lesions. The use of contrast enhancement in addition to plain CT scans increases the reliability of CT scans in excluding such conditions as neoplasms, abscesses, and vascular malformations. Because the use of contrast medium is associated with morbidity (and significantly extends the length of the total study), the decision to employ contrast enhancement must be based upon a careful evaluation of the clinical, other radiological, and plain CT findings in the individual patient.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 866885

Source DB:  PubMed          Journal:  Rev Interam Radiol        ISSN: 0034-9704


  3 in total

1.  50th anniversary of computed tomography: past and future applications in clinical neuroscience.

Authors:  William P Dillon
Journal:  J Med Imaging (Bellingham)       Date:  2021-10-18

2.  Usefulness of 11C-methionine positron emission tomography for detecting intracranial ameloblastic carcinoma: A case report.

Authors:  Akira Tempaku; Yoshinobu Takahashi; Hidetoshi Ikeda; Shigeru Yamauchi; Takashi Gotoh; Nobuyuki Bandoh; Syujirou Makino; Takuji Shimada; Hajime Kamada
Journal:  Oncol Lett       Date:  2014-07-15       Impact factor: 2.967

3.  Contrast media-assisted in-treatment cone beam CT during single-isocentre volumetric-modulated arc therapy for multiple brain metastases: a case study.

Authors:  Akihiro K Nomoto; Wataru Takahashi; Hideomi Yamashita; Akihiro Haga; Kiyoshi Yoda; Keiichi Nakagawa
Journal:  BJR Case Rep       Date:  2016-09-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.